Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
Reuters10/16/2026Negative
NVS
Novartis AG ADRNYSEHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$285.83B
P/E Ratio
22.72
EPS
$6.62
Beta
0.47
52W High
$165.43
52W Low
$117.98
50-Day MA
$148.31
200-Day MA
$151.04
Dividend Yield
3.15%
Profit Margin
22.50%
Forward P/E
14.71
PEG Ratio
3.34
About Novartis AG ADR
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Fundamentals
| Revenue (TTM) | $56.69B |
| Gross Profit (TTM) | $42.51B |
| EBITDA | $23.10B |
| Operating Margin | 34.60% |
| Return on Equity | 30.30% |
| Return on Assets | 10.20% |
| Revenue/Share (TTM) | $29.64 |
| Book Value | $21.86 |
| Price-to-Book | 6.53 |
| Price-to-Sales (TTM) | 5.04 |
| EV/Revenue | 5.53 |
| EV/EBITDA | 13.97 |
| Quarterly Earnings Growth (YoY) | -17.00% |
| Quarterly Revenue Growth (YoY) | 0.80% |
| Shares Outstanding | $1.90B |
| Float | $1.86B |
| % Insiders | 0.01% |
| % Institutions | 7.26% |
Historical Volatility
HV 10-Day
20.54%
HV 20-Day
19.18%
HV 30-Day
47.67%
HV 60-Day
38.82%
HV Rank
89.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($154.65 target)
3
Strong Buy2
Buy6
Hold1
SellLatest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire10/15/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire10/13/2026Neutral
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
Zacks Investment Research10/8/2026Positive
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire10/8/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire10/6/2026Neutral
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
Zacks Investment Research10/5/2026Positive
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the past two weeks.
CNBC10/2/2026Positive
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
Abogen said its lead drug has potential to transform the treatment landscape for patients with autoimmune diseases.
WSJ10/2/2026Positive
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire10/1/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVS and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/17/2026